Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study-Reference-Cited by-同舟云学术

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Published:2020-05 Issue:5 Volume:21 Page:671-684
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Abou-Alfa Ghassan K,Sahai Vaibhav,Hollebecque Antoine,Vaccaro Gina,Melisi Davide,Al-Rajabi Raed,Paulson Andrew S,Borad Mitesh J,Gallinson David,Murphy Adrian G,Oh Do-Youn,Dotan Efrat,Catenacci Daniel V,Van Cutsem Eric,Ji Tao,Lihou Christine F,Zhen Huiling,Féliz Luis,Vogel Arndt

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Pathogenesis, diagnosis, and management of cholangiocarcinoma;Rizvi;Gastroenterology,2013

2. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention;Lowery;Clin Cancer Res,2018

3. Advances and challenges in targeting FGFR signalling in cancer;Babina;Nat Rev Cancer,2017

4. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles;Farshidfar;Cell Rep,2017

5. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing;Ross;Oncologist,2014

Cited by 1077 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholangiocarcinoma;Treatment and Management of Tropical Liver Disease;2025

2. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

3. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10

4. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

5. Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden;Journal of Gastrointestinal Cancer;2024-09-10